Homocysteine in the Plasma of Renal Transplant Recipients: Effects of Cofactors for Methionine Metabolism

1981 ◽  
Vol 61 (6) ◽  
pp. 743-749 ◽  
Author(s):  
D. E. L. Wilcken ◽  
Vatsala J. Gupta ◽  
A. K. Betts

1. Homocysteine which is formed during the metabolism of methionine is readily oxidized and is measured by the amino acid analyser as cysteine—homocysteine mixed disulphide and homocystine. We measured plasma amino acid concentrations after an overnight fast in 27 stable long-term renal transplant recipients and 25 age-and sex-matched normal subjects with particular emphasis on sulphur-containing amino acids. 2. Plasma cysteine—homocysteine mixed disulphide was increased in the patients (mean 6.0 ± sd 3.2 μmol/l; normal 3.1 ± 0.9 μmol/l, P < 0.001) and homocystine was detectable in low concentration (< 1.0 μmol/l) in 24; the elevation in cysteine—homocysteine was related to serum creatinine (r = 0.60, P < 0.002). Cystine was also increased (91.6 ± 29.3 μmol/l; normal subjects 64.0 ± 16.7 μmol/l, P < 0.001), but methionine concentrations were normal. 3. When pyridoxine, folic acid and vitamin B12, cofactors for homocysteine metabolism, were administered sequentially to 11 arbitrarily selected transplant recipients cysteine—homocysteine decreased from 7.3 ± 2.1 to 4.3 ± 0.8 μmol/l (P < 0.001) and homocystine became undetectable. the response coincided with the giving of folic acid and occurred without alteration in serum creatinine and with normal serum folate and vitamin B12 concentrations. 4. in eight patients in whom pretreatment erythrocyte folate was measured, folic acid therapy reduced cysteine—homocysteine from 9.0 ± 3.1 to 5.4 ± 1.6 μmol/l over a 4 week period (P < 0.001), the largest response being in the one patient with subnormal erythrocyte folate; values were in the low-normal or normal range in the other seven. 5. We conclude that plasma homocysteine is increased in renal transplant recipients when serum creatinine is only moderately elevated and that the homocysteine concentrations are decreased by treatment with folic acid, suggesting that both reduced homocysteine excretion and relative shortages of folic acid are responsible.

2000 ◽  
Vol 55 (5) ◽  
pp. 161-168 ◽  
Author(s):  
David José de Barros Machado ◽  
Flávio Jota de Paula ◽  
Emil Sabbaga ◽  
Luiz Estevan Ianhez

PURPOSE: Hyperhomocyst(e)inaemia is an important risk factor for atherosclerosis, which is currently a major cause of death in renal transplant patients. The aim of this study was to assess the influence of immunosuppressive therapy on homocyst(e)inemia in renal transplant recipients. METHODS: Total serum homocysteine (by high performance liquid chromatography), creatinine, lipid profile, folic acid (by radioimmunoassay-RIA) and vitamin B12 (by RIA) concentrations were measured in 3 groups. Group I patients (n=20) were under treatment with cyclosporine, azathioprine, and prednisone; group II (n=9) were under treatment with azathioprine and prednisone; and group III (n=7) were composed of renal graft donors for groups I and II. Creatinine, estimated creatinine clearance, cyclosporine trough level, lipid profile, folic acid, and vitamin B12 concentrations and clinical characteristics of patients were assessed with the aim of ascertaining determinants of hyperhomocyst(e)inemia. RESULTS: Patient ages were 48.8 ± 15.1 yr (group I), 43.3 ± 11.3 yr (group II); and 46.5 ± 14.8 yr (group III). Mean serum homocyst(e)ine (tHcy) concentrations were 18.07 ± 8.29 mmol/l in renal transplant recipients; 16.55 ± 5.6 mmol/l and 21.44 ± 12.1 mmol/l respectively for group I (with cyclosporine) and group II (without cyclosporine) (NS). In renal donors, tHcy was significantly lower (9.07 ± 3.06 mmol/l; group I + group II vs. group III, p<0.008). There was an unadjusted correlation (p<0.10) between age (r=0.427; p<0.005) body weight (r=0.412; p<0.05), serum creatinine (r=0.427; p<0.05), estimated creatinine clearance (r=0.316; p<0.10), and tHcy in renal recipients (group I +II). Independent regressors (r²=0.46) identified in the multiple regression model were age (coefficient= 0.253; p=0.009) and serum creatinine (coefficient=8.07; p=0.045). We found no cases of hyperhomocyst(e)inemia in the control group. In contrast, 38% of renal recipients had hyperhomocyst(e)inemia: 7 cases (35%) on cyclosporine and 4 (45%) without cyclosporine, based on serum normal levels. CONCLUSIONS: Renal transplant recipients frequently have hyperhomocyst(e)inemia. Hyperhomocyst(e)inemia in renal transplant patients is independent of the scheme of immunosuppression they are taking. The older the patients are and the higher are their serum creatinine levels, the more susceptible they are to hyperhomocyst(e)inemia following renal transplantation.


2001 ◽  
Vol 33 (1-2) ◽  
pp. 2049-2050 ◽  
Author(s):  
B Grandtnerová ◽  
L Laca ◽  
D Gábor ◽  
E Gregová ◽  
S Korónyi

2007 ◽  
Vol 39 (10) ◽  
pp. 3163-3165 ◽  
Author(s):  
P.M. Biselli ◽  
M.P. Sanches de Alvarenga ◽  
M. Abbud-Filho ◽  
M.A.S. Ferreira-Baptista ◽  
A.L.S. Galbiatti ◽  
...  

1999 ◽  
Vol 10 (1) ◽  
pp. 164-166 ◽  
Author(s):  
ANDREW G. BOSTOM ◽  
REGINALD Y. GOHH ◽  
LINDA BAUSSERMAN ◽  
DAVID HAKAS ◽  
PAUL F. JACQUES ◽  
...  

Abstract. Serum creatinine, a surrogate for both renal function and homocysteine generation, is an important determinant of fasting plasma total homocysteine levels in stable renal transplant recipients. In this study, it is hypothesized that among stable renal transplant recipients with normal creatinine levels (i.e., ≤ 1.5 mg/dl), serum cystatin C, a more sensitive indicator of GFR, would better predict fasting total homocysteine levels compared with serum creatinine. Fasting plasma total homocysteine, folate, vitamin B12, and pyridoxal 5′-phosphate levels, along with serum cystatin C, creatinine, and albumin levels, were determined in 28 consecutive renal transplant recipients (mean age 47 ± 14 yr; 60.7% men) with stable allograft function, whose serum creatinine was ≤1.5 mg/dl. General linear modeling with analysis of covariance revealed that serum cystatin C was independently predictive (partial R = 0.494; P = 0.023) of fasting total homocysteine levels after adjustment for age, gender, vitamin status, albumin, and creatinine levels. In contrast, creatinine levels were not predictive of fasting total homocysteine levels in this model (P = 0.110) or an identical model that excluded cystatin C (P = 0.131). Serum cystatin C levels may reflect subtle decreases in renal function that independently predict fasting total homocysteine levels among stable renal transplant recipients with a normal serum creatinine.


2002 ◽  
Vol 73 (4) ◽  
pp. 663-665 ◽  
Author(s):  
Aboubakr Abdelfatah ◽  
Didier Ducloux ◽  
G??rard Toubin ◽  
G??rard Motte ◽  
Daniel Alber ◽  
...  

Blood ◽  
1964 ◽  
Vol 24 (5) ◽  
pp. 502-521 ◽  
Author(s):  
BERNARD A. COOPER ◽  
LOUIS LOWENSTEIN

Abstract 1. A relationship has been observed between the serum and erythrocyte folate in normal subjects. 2. Patients with folate deficiency were more readily differentiated from normal subjects by determinations of serum folate activity than by determinations of erythrocyte folate activity. 3. In pernicious anemia in relapse, accumulation of serum folate and/or depletion of erythrocyte folate was observed in all patients, resulting in a disturbance of the normal relationship between the serum and erythrocyte folate activity. This altered relationship was corrected following the reticulocytosis induced by vitamin B12 therapy. 4. Patients receiving amethopterin therapy appear to incorporate the folate antagonist into maturing erythroid cells, since the erythroid cells so formed showed anti-bacterial activity for several weeks following the administration of the antagonist. 5. Preliminary fractionation of folate co-enzymes in erythroid cells of a patient with pernicious anemia before and after therapy revealed no significant difference in the distribution of the co-enzymes induced by therapy. A significant proportion of the folate activity of the erythroid cells was found in a fraction eluted from the DEAE column by sodium hydroxide. 6. The data presented are consistent with a direct effect of vitamin B12 on folate transport into the erythroblast.


2017 ◽  
Vol 82 (6) ◽  
pp. 1000-1006 ◽  
Author(s):  
Omar Alkandari ◽  
Diane Hebert ◽  
Valerie Langlois ◽  
Lisa A Robinson ◽  
Rulan S Parekh

Renal Failure ◽  
2016 ◽  
Vol 38 (9) ◽  
pp. 1418-1424 ◽  
Author(s):  
Tahereh Hasannia ◽  
Seyed Majid Moosavi Movahed ◽  
Rosita Vakili ◽  
Houshang Rafatpanah ◽  
Reza Hekmat ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document